The US Anthrax Vaccine Market Size was valued at USD 5.9 billion in 2023. The industry is projected to grow from USD 6.1 billion in 2024 to USD 8.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00% during the forecast period (2024 - 2032). An increase in government contracts and funding and rising demand for biodefense preparedness are the primary market drivers propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The creation of anthrax vaccines with improved safety profiles is made possible by cutting down on the possibility of side effects and boosting public trust in vaccination programs, which is driving the market CAGR. Examples of these advanced vaccine technologies include protein subunit vaccines and recombinant DNA approaches. By focusing on certain anthrax bacteria components, next-generation vaccine platforms allow the development of anthrax vaccinations with increased efficacy, improving infection prevention and minimizing the need for booster doses. By boosting vaccine efficiency and cost-effectiveness and maybe lowering the number of doses needed for protection, novel adjuvants can strengthen the immune response to anthrax vaccinations, improving their efficacy and potentially propelling market development.
Additionally, early detection of anthrax outbreaks by surveillance systems enables quick action by the public health community. The discovery of anthrax cases may lead to vaccination drives and stockpiling initiatives, which in turn may increase demand for the vaccine. The utilization of surveillance data yields significant insights into evaluating the potential for anthrax exposure across various geographic areas or demographic groups. The industry is growing because enhanced readiness initiatives, such as immunization campaigns and procurement agreements, are frequently directed by surveillance results. Public health organizations use surveillance systems to guide their response plans for anthrax outbreaks, which include resource allocation and vaccination preparations. Investment in anthrax vaccines and associated infrastructure is driven by the requirement for readiness, which propels market expansion.
Furthermore, animals affected with anthrax illness, which affects cattle and other ruminants, die. The soil-borne spore-forming bacterium Bacillus anthracis is the cause of this zoonotic illness, which affects both people and animals in the United States. Because of growing efforts by industry participants to create animal vaccines and growing awareness among animal owners about anthrax vaccination, the animal-use anthrax vaccine sector is anticipated to hold a sizable market share throughout the projected period. Thus, this drives the US Anthrax Vaccine market revenue.
Based on Vaccine Type, the US Anthrax Vaccine market segmentation includes cell-free PA vaccine, anthrax vaccine adsorbed (AVA), anthrax vaccine precipitated (AVP), and live attenuated vaccine. In 2023, the cell-free PA vaccine segment dominated the market. The goal of the cell-free PA vaccine is to increase the body's ability to produce antibodies against the protective antigen (PA) found in the anthrax toxin. In order for the anthrax bacteria to infect cells and spread illness, PA is required. The vaccination seeks to prevent anthrax infection by neutralizing the toxin via targeting PA. Cell-free protein synthesis methods are used in the production of the Cell-Free PA Vaccine, in contrast to conventional anthrax vaccines that are made with live or attenuated bacteria. This novel manufacturing technique has a number of benefits, including scalability, less danger of contamination, and exact control over protein output.
The anthrax vaccine Adsorbed (AVA) category is anticipated to be the fastest growing. AVA is regularly administered to US military faculty as a component of the Department of Defense's (DoD) Bacillus anthracis Immunization Vaccination Program (AVIP). Military personnel deployed to The vaccination is necessary to guard against possible anthrax exposure in high-risk locations or when allocated to particular occupational duties.
Based on Applications, the US Anthrax Vaccine market segmentation includes animal use and human use. The category with the highest income generation in 2023 was animal use. To prevent anthrax outbreaks on farms and ranches, livestock, including cattle, sheep, and goats, are vaccinated against the disease in the United States. Vaccinating cattle is essential for maintaining animal health and avoiding financial losses brought on by anthrax-related fatalities and disease outbreaks. In high-risk locations or places with a history of anthrax outbreaks, government organizations, such as the US Department of Agriculture (USDA) and state veterinary authorities, may conduct anthrax vaccination programs for cattle. The goals of these initiatives are to reduce the impact on agricultural output and manage the spread of anthrax.
The US Anthrax Vaccine human use portion market is expected to grow quickly during the forecast time frame. AVA can be used for post-exposure prophylaxis (PEP) to prevent anthrax infection in anyone who may have been exposed to the bacteria in the case of a confirmed or suspected anthrax exposure. It is advised to combine PEP with AVA, antibiotics, and other medical treatments.
Figure 1: US Anthrax Vaccine Market, by Applications, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on the Distribution Channel, the US Anthrax Vaccine market segmentation includes hospitals, pharmacies, and other distribution channels. The hospitals category leads the market. Vaccination standards and public health recommendations permit hospitals with immunization clinics or occupational health departments to provide AVA to emergency responders, medical staff, and other high-risk persons. Hospitals have the option to engage in community outreach programs aimed at increasing public knowledge of the anthrax vaccine, endorsing vaccination drives, and furnishing them with details on vaccine accessibility, qualifying requirements, and administration periods.
The US Anthrax Vaccine market’s pharmacies segment is anticipated to grow fastest during the projection period. The distribution and administration of vaccines, such as AVA, during anthrax epidemics or bioterrorism occurrences are among the public health emergency preparation initiatives in which pharmacies may take part. Under some circumstances, pharmacists could be permitted to provide AVA to people who have been classified as high-risk or who qualify for immunization.
The US is a hub for vaccine innovative work, with government organizations, drug partnerships, and academic institutions effectively attempting to propel Bacillus anthracis vaccine innovation. Cutting-edge Bacillus anthracis vaccine improvement is filled by interests in research, clinical preliminaries, and item development, all of which support market extension. The US government places a high priority on being ready for biodefense. This may result in a build-up of anthrax vaccine supplies and the possibility of tailored immunization campaigns for high-risk populations. The United States makes significant investments in biodefense R&D. This may result in the development of anthrax vaccinations that are more effective, simpler to administer, or combine protection against many hazards.
US Anthrax Vaccine Key Market Players & Competitive Insights
The industry's leading players will keep investing heavily in R&D to expand their product lines, which will propel the US Anthrax Vaccine market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the US Anthrax Vaccine industry must offer reasonably priced products and services.
One of the main strategies manufacturers use in the worldwide US Anthrax Vaccine market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the US Anthrax Vaccine sector. Major players in the US Anthrax Vaccine market, including Merck & Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., PharmAthene, Inc., Biogenesis Bago S.A, Porton Biopharma Limited, Colorado Serum, Merial, Inc., Tiankang, Agrovet, Bayer AG, and others, are attempting to increase market demand by investing in research and development operations.
A biopharmaceutical company, Merck and Co. Inc. is committed to the research, development, manufacture, and marketing of biologic therapies, pharmaceuticals recommended by doctors, vaccines, and products for the health of animals. It provides prescription products for the treatment of conditions related to cancer, diabetes, heart disease, respiratory, infectious, immune, and other conditions. The company offers products for animal health, including hydroponics, chicken, antibodies, and animals. Merck supplies managed medical care providers, veterinarians, businesses, and animal producers with pharmaceuticals and animal welfare products.
A life sciences business called Emergent BioSolutions Inc. offers specialized solutions to meet medical requirements and public health threats (PHTs). Chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious illnesses, and acute/emergency care are among the PHTs that its solutions assist in addressing. It provides contract development and manufacturing services in addition to vaccines, medicines, and drug-device combo products. The pipeline prospects of Emergent are intended to treat influenza and dengue fever. Additionally, it provides government agencies and private clients with specific products.
Key companies in the US Anthrax Vaccine market include
US Anthrax Vaccine Industry Developments
October 2022: The US Biomedical Advanced Research and Development Authority (BARDA), a division of the Department of Health and Human Services (HHS)'s Administration for Strategic Preparedness and Response (ASPR), has chosen ICON plc to carry out a clinical study for the anthrax vaccine AV7909. The vaccine is presently being evaluated in clinical trials.
June 2022: Emanant BioSolutions Inc. was granted review acceptance of the Biologics Permit Application (BLA) for AV7909 (Bacillus anthracis Immunization Adsorbed, Adjuvanted) from the US FDA. AV7909 is assessed for post-exposure prophylaxis of illness following thought or exposure openness to Bacillus anthracis in adults (age bunch 18 - 65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 5.9 Billion |
| Market Size 2024 | USD 6.1 Billion |
| Market Size 2032 | USD 8.7 Billion |
| Compound Annual Growth Rate (CAGR) | 5.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Vaccine Type, Applications, and Distribution Channel |
| Countries Covered | US |
| Key Companies Profiled | Merck & Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., PharmAthene, Inc, Biogenesis Bago S.A, Porton Biopharma Limited, Colorado Serum, Merial, Inc., Tiankang, Agrovet, and Bayer AG |
| Key Market Opportunities | · Increasing concerns about bioterrorism and emerging infectious diseases and investment in research and development |
| Key Market Dynamics | · Increase government contracts and funding and rising demand for biodefense preparedness. |
Frequently Asked Questions (FAQ) :
The US Anthrax Vaccine market size was valued at USD 5.9 Billion in 2023.
The US Anthrax Vaccine market is projected to grow at a CAGR of 5.00% during the forecast period, 2024-2032.
The key players in the market are Merck & Co., Inc., Emergent Bio-Solutions, Zoetis, Inc., PharmAthene, Inc., Biogenesis Bago S.A, Porton Biopharma Limited, Colorado Serum, Merial, Inc., Tiankang, Agrovet, and Bayer AG.
The Cell-Free PA Vaccine category dominated the market in 2023.
Animal Use had the largest share in the US Anthrax Vaccine market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
